Correlation of Histopathological Findings in Laryngeal Squamous Cell Carcinoma with Inflammatory Biomarkers

Year 2019, Volume: 9 Issue: 1, 44 - 52, 19.03.2019

İldem Deveci Mehmet Surmeli Serap Onder Burak Karabulut Hande Senem Deveci Cagatay Oysu

Abstract

Objective: The goal of this research was to investigate how biomarkers, i.e. SII (an index calculated from blood counts of various leucocytes), NLR and MLR correlate with features used in the staging of laryngeal squamous cell carcinoma (LSCC), i.e. perineural infiltration, lymphatic involvement and histological grade.

Methods:A retrospective review of clinical records from 146 cases (143 men and 3 women) of LSCC occurring between January 2008 and January 2018 was undertaken. The sample included every stage of LSCC and all biomarker results were found from the full blood count (FBC) results obtained prior to surgery and documented for each case. SII is a newly introduced index of inflammation calculated according to the formula: SII = NxP/L, where N represents neutrophil, P platelet and L lymphocyte counts.  Histopathological parameters (presence of perineural or lymphatic involvement, grade of tumour) were evaluated alongside results for NLR, MLR and SII.

Results:All three biomarkers were different at the level of statistical significance between individuals with LSCC and the controls. For NLR, p=0.003; for MLR, p=0.008; for SII, p<0.001.

Both NLR and SII were different at a statistically significant level when compared at early and advanced stages of LSCC (p values were 0.011 and <0.001, respectively. MLR did not differ at the level of statistical significance (p=0.944). (See Table 3).

Conclusion:SII is straightforward to calculate, economical and reproducible from FBC results. It can provide important clues to the likelihood of perineural or lymphatic involvement in cases of LSCC.

Keywords

Laryngeal squamous cell carcinoma, inflammatory biomarkers

References

• 1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin 2016; 66: 7-30
• 2. Paget-Bailly S, Cyr D, Luce D. Occupational exposures and cancer of the larynx systematic review and meta-analysis. J Occup Environ Med 2012; 54:71-84
• 3. Huang SH, O'Sullivan B. Overview of the 8th Edition TNM Classification for Head and Neck Cancer. Curr Treat Options Oncol 2017; Jul;18(7):40
• 4. Yilmaz T, Hosal AS, Gedikoglu G, et al. Prognostic significance of vascular and perineural invasion in cancer of the larynx. Am J Otolaryngol 1998; Mar-Apr;19(2):83-88
• 5. Coussens LM, Werb Z. Inflammation and cancer. Nature Dec 2002;19-26;420(6917):860-867
• 6. Kum RO, Ozcan M, Baklaci D, et al. Elevated neutrophil-to-lymphocyte ratio in squamous cell carcinoma of larynx compared to benign and precancerous laryngeal lesions. Asian Pac J Cancer Prev 2014; 15:7351–7355
• 7. Mascarella MA, Mannard E, Daniela Silva Wurzba S, Zeitouni A. Neutrophil-to-lymphocyte ratio in head and neck cancer prognosis: A systematic review and meta-analysis. Head Neck 2018; Jan 22. doi: 10.1002/hed.25075
• 8. Kara M, Uysal S, Altinisik U, et al. The pre-treatment neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and red cell distribution width predict prognosis in patients with laryngeal carcinoma. Eur Arch Otorhinolaryngol 2017; Jan;274(1):535-542
• 9. Nishijima TF, Muss HB, Shachar SS, et al. Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: A systematic review and meta-analysis. Cancer Treat Rev 2015; Dec;41(10):971-978
• 10. Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res 2014; 20:6212–6222
• 11. Geng Y, Shao Y, Zhu D, et al. Systemic Immune-Inflammation Index Predicts Prognosis of Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score-matched Analysis. Sci Rep 2016; 6:39482.
• 12. Hong X, Cui B, Wang M, Yang Z, et al. Systemic Immune-inflammation Index, Based on Platelet Counts and Neutrophil-Lymphocyte Ratio, Is Useful for Predicting Prognosis in Small Cell Lung Cancer. Tohoku J Exp Med 2015; 236:297–304
• 13. Lolli C, Basso U, Derosa L, et al. Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Oncotarget 2016; 7:54564–54571
• 14. Passardi A, Scarpi E, Cavanna L, et al. Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. Oncotarget 2016; 7:33210–33219
• 15. Jiang W, Chen Y, Huang J, et al. Systemic immune-inflammation index predicts the clinical outcome in patients with nasopharyngeal carcinoma: a propensity score-matched analysis. Oncotarget 2017; Aug 2;8(39):66075-66086
• 16. Eltohami YI, Kao HK, Lao WW, Huang Y, Abdelrahman M, Liao CT, Yen TC, Chang KP. The Prediction Value of the Systemic Inflammation Score for Oral Cavity Squamous Cell Carcinoma. Otolaryngol Head Neck Surg 2018; Jan 1:194599817751678. doi: 10.1177/0194599817751678.
• 17. De Larco JE, Wuertz BR, Furcht LT. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res 2004; Aug 1;10(15): 4895-4900
• 18. McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003; Feb;90(2):215-9
• 19. Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258:1798 -1801
• 20. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011; 11:123–134
• 21. Rothwell PM, Price JF, Fowkes FGR et al. Shortterm effects of daily aspirin on cancer incidence, mortality, and non-vascular death. Lancet 2012; 379: 1602–1612
• 22. Qian BZ, Pollard J. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39-51
• 23. Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers 2014; 6: pp. 1670-1690
• 24. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; Aug;21(2):137-148
• 25. Ownby HE, Roi LD, Isenberg RR, Brennan MJ. Peripheral lymphocyte and eosinophil counts as indicators of prognosis in primary breast cancer. Cancer 1983;52: 126–130
• 26. Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a Prognostic Factor For Overall Survival in Advanced Carcinomas, Sarcomas And Lymphomas. Cancer research 2009; 69(13):5383-5391
• 27. Mallappa S, Sinha A, Gupta S, Chadwick SJD. Preoperative neutrophil to lymphocyte ratio >5 is a prognostic factor for recurrent colorectal cancer. The Association of Coloproctology of Great Britain and Ireland 2013; 15, 323-328
• 28. Chandrasekara S, Davis S, Thomson P, Haydon A. High neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy. Asia Pac J Clin Oncol. 2018 Jan 17. doi: 10.1111/ajco.12846.
• 29. Park YM, Oh KH, Cho JG, et al. A prognostic scoring system using inflammatory response biomarkers in oral cavity squamous cell carcinoma patients who underwent surgery-based treatment. Acta Otolaryngol 2017; Nov 23:1-6.
• 30. Zhong JH, Huang DH, Chen ZY. Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis. Oncotarget 2017; 8(43):75381-75388